COVER ILLUSTRATION. Transaxial projection of statistical parametric maps for between-group comparison showing areas of significant between-group differences in 11C-raclopride binding potential (an indicator of striatal dopaminergic D2 receptor binding) for a group of normal subjects and patients with Huntington's disease. The picture at the bottom shows the decreases of raclopride binding potential in amygdala. From `Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study.' by N. Pavese et al., pp. 1127-1135.
[Table of Contents]